Pfizer 2009 Annual Report Download - page 25

Financial Review
Pfizer Inc. and Subsidiary Companies
•Geodon/Zeldox, a psychotropic agent, is a dopamine and serotonin receptor antagonist indicated for the treatment of schizophrenia,
and acute manic or mixed episodes associated with bipolar disorder and maintenance treatment of bipolar mania. Geodon recorded a
decrease in worldwide revenues of 1% in 2009 compared to 2008 due to increased generic competition, slow growth in the
antipsychotic market in the U.S., as well as the unfavorable impact of foreign exchange.
•Sutent is for the treatment of advanced renal cell carcinoma, including metastatic renal cell carcinoma, and gastrointestinal stromal
tumors after disease progression on, or intolerance to, imatinib mesylate. Sutent worldwide revenues increased 14% in 2009 compared
to 2008. We continue to drive total revenue and prescription growth, supported by cost-effectiveness data and efficacy data in first-line
mRCC—including two-year survival data, which represent the first time overall survival of two years has been seen in the treatment of
advanced kidney cancer, as well as through access and healthcare coverage. As of December 31, 2009, Sutent was the best-selling
medicine in the world for the treatment of first-line mRCC.
•Genotropin, the world’s leading human growth hormone, is used in children for the treatment of short stature with growth hormone
deficiency, Prader-Willi Syndrome, Turner Syndrome, Small for Gestational Age Syndrome, Idiopathic Short Stature (in the U.S. only)
and Chronic Renal Insufficiency (outside the U.S. only), as well as in adults with growth hormone deficiency. Genotropin is supported
by a broad platform of innovative injection-delivery devices. Genotropin worldwide revenues decreased 1% in 2009 compared to 2008,
as the unfavorable impact of foreign exchange more than offset the operational revenue increase.
•Vfend, as the only branded agent available in intravenous and oral forms, continues to build on its position as the best-selling systemic,
antifungal agent worldwide. The overall global revenues of Vfend continue to be driven by its acceptance as an excellent broad-
spectrum agent for treating yeast and molds. Vfend worldwide revenues increased 7% in 2009 compared to 2008.
See Notes to Consolidated Financial Statements—Note 19. Legal Proceedings and Contingencies for a discussion of certain
patent litigation relating to Vfend.
•Chantix/Champix, the first new prescription treatment to aid smoking cessation in nearly a decade, has been launched in all major
markets. Chantix/Champix worldwide revenues in 2009 decreased 17% compared to 2008 due to changes to the product’s label and
other factors. We are continuing our educational and promotional efforts, which are focused on the Chantix benefit-risk proposition, the
significant health consequences of smoking and the importance of the physician-patient dialogue in helping patients quit smoking.
In January 2008, we added a warning to the Chantix label that patients who are taking Chantix should be observed by a physician
for neuropsychiatric symptoms. In May 2008, we updated the Chantix label to provide further guidance about the safe use of
Chantix. The updated label advises that patients should stop taking Chantix and contact their healthcare provider immediately if
agitation, depressed mood or changes in behavior that are not typical for them are observed or if they develop suicidal thoughts
or suicidal behavior.
In July 2009, we further updated the Chantix label to highlight reports of serious neuropsychiatric events in a boxed warning;
updated the warning about reports of neuropsychiatric symptoms and suicidality; added warnings about reports of allergic
reactions and serious skin reactions; and updated precautionary information about driving or operating machinery to include
details about reports of accidental injury. The boxed warning about reports of serious neuropsychiatric events was also added to
the labels of prescription smoking-cessation aids produced by other pharmaceutical companies. Additionally, the boxed warning
communicates that the health benefits of quitting smoking are immediate and substantial, that the risk of Chantix should be
weighed against the benefit of its use and that Chantix has been demonstrated to increase the likelihood of quitting for as long as
one year compared to placebo. These updates will help further enhance discussions between physicians and patients about the
benefits and risks of Chantix.
•Caduet, a single-pill therapy combining Norvasc and Lipitor, recorded decreases in worldwide revenues of 7% in 2009 compared to
2008, primarily due to increased generic competition, as well as an overall decline in U.S. hypertension market volume.
See Notes to Consolidated Financial Statements—Note 19. Legal Proceedings and Contingencies for a discussion of certain
patent litigation relating to Caduet.
•Effexor is our antidepressant for treating adult patients with major depressive disorder, generalized anxiety disorder, social anxiety
disorder and panic disorder. Effexor faces generic competition outside the U.S. In the U.S., Effexor faces competition from a
non-AB-rated (i.e., not therapeutically equivalent) generic product. Pursuant to a 2005 settlement agreement related to certain patent
litigation with Wyeth, Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. are permitted to launch generic
versions of Effexor XR (extended release capsules) in the U.S. beginning July 1, 2010 subject to possible earlier launch based on
specified market conditions or developments regarding the applicable patents rights, including the outcome of other generic challenges
to such patent rights.
See Notes to Consolidated Financial Statements—Note 19. Legal Proceedings and Contingencies for a discussion of certain
patent litigation relating to Effexor.
•Revatio, for the treatment of pulmonary arterial hypertension, recorded an increase in worldwide revenues of 34% in 2009 compared to
2008, primarily due to the recent FDA approval of enhanced labeling and market trends toward earlier diagnosis and treatment.
•Enbrel is our treatment for rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis and ankylosing
spondylitis, a type of arthritis affecting the spine. The approval of competing products for the treatment of psoriasis is expected to
increase competition with respect to Enbrel in 2010.
2009 Financial Report 23